Back to search results

Radiation for Joint Damage from Cancer Immunotherapy

This study is looking into a treatment called low dose radiation therapy (LDRT) for joint pain and damage (arthritis or arthropathy) caused by cancer immunotherapy. You might be able to join if you are 40 or older, have cancer that has spread or can't be removed, and are currently receiving immunotherapy or received it within the last six months. You also need to have a diagnosis from a rheumatologist (a doctor specializing in joint and muscle diseases) of new or worsening joint inflammation from immunotherapy. The study will give you 0.5 Gy of radiation per treatment, 6 times over 2-3 weeks. Researchers will measure how well the radiation therapy works at 3 months after you enroll. This study is currently recruiting 20 participants to see if this treatment is safe and possible.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.
What's involved
You would receive 6 low dose radiation treatments, given 2-3 times per week over 2-3 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your response to radiation therapy will be measured at 3 months after you enroll.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07478679

Radiation to Treat Joint Damage Caused by Cancer Immunotherapy

Not Yet Recruiting
PHASE1Ages 40+InterventionalTreatment
University of Chicago
~20 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:Low dose radiation therapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Radiation therapy
Measured over 3 months post enrollment.

Conditions

Arthritis
Arthropathy

Explore related trials

ArthritisSolid Neoplasm

NCT07478679

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinoisstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Pankti Reid · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Clinical Trials Intake
[email protected]
855-702-8222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which they are receiving single agent or combination immunotherapy or within the last 6 months.
Rheumatologist-established diagnosis of new onset CTCAE grade 2-3 immunotherapy-induced inflammatory arthritis or activated osteoarthritis, involving one or more joints (up to 3) including but not limited to hands, shoulders, elbows, hips, knees and ankles.
Age ≥ 40 years.
ECOG performance status ≤2 (Karnofsky ≥60%).
Patients with ability and willingness to sign consent.

Exclusion

Contraindications to radiation treatment, such as pregnancy, breast-feeding women and active collagen-vascular disease.
Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \>1 year prior to consent and/or clear documentation states that the patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment.
Have not received systemic steroids within the last 3 months for the treatment of immune related adverse events.
History of prior autoimmune conditions, or concurrent immune related adverse events requiring systemic immunosuppressants.
Estimated life expectancy less than 3 months as assessed by investigators.
Any condition at the discretion of investigator that will preclude participation in the study.
History of secondary malignancy as assessed by investigators.
History of radiation to affected joints as assessed by investigators.

What this trial measures

  • Radiation therapy3 months post enrollment.

    To assess the safety and feasibility of administering Low dose radiation therapy (LDRT) in patients with immunotherapy-induced arthritis. Number of patients that experience at least one treatment related Common Terminology Criteria for Adverse Events (CTCAE) grade 4 or 5 side effect.